April 21, 2017
Janssen Pharmaceutical said on April 20 that it has filed a new drug application in Japan for its human monoclonal anti-interleukin (IL)-23 antibody guselkumab for the treatment of psoriasis. The company is seeking approval for the indications of plaque psoriasis,...read more